

## HCV Conference: The Changing Paradigm

– April 27, 2011 –

### REFERENCES

◇ Included as a PDF on  
your CDAAR flash drive

#### Hepatitis C Treatment Guidelines

1. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; 49:1335-74. <http://www.ncbi.nlm.nih.gov/pubmed/19330875>
2. Sulkowski MS, Cheever LW, Spach DH. A guide for evaluation and treatment of hepatitis C in adults coinfecting with HIV. US Department of Health and Human Services, Health Resources and Services Administration (HRSA) (January 14, 2011) <http://hab.hrsa.gov/publications/hcvguide2011.pdf>
3. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR Recomm Rep.* 1998 Oct 16;47(RR-19):1-39. <http://www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm>
4. Rockstroh JK, Bhagani S, et al. European AIDS clinical Society guideline for the clinical management and treatment of chronic HCV and HCV coinfection in HIV-infected Adults. *HIV Medicine* 2008; 9:82-88.

#### New Therapeutic Agents for Hepatitis C

- **New Agents – General reviews:**

1. Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. *Gastroenterology & Hepatology* 2011; 7:154-162.
2. Fusco DN, Chung RT. New protease inhibitors for HCV – Help is on the way. *J Hepatol* 2011; (in press)
3. Swan T. The hepatitis C treatment pipeline report. Treatment Action Group. (March 2011) [www.treatmentactiongroup.org](http://www.treatmentactiongroup.org).
4. Pawlotsky J-M. The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. *Gastroenterology* 2011; 140:746-760.
5. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy. *Alimentary Pharmacology and Therapeutics* 2010; 32:14-28.
6. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. *Gastroenterology* 2010; 138:447-62.

7. Seden K, Back D, Khoo S: New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. *J Antimicrob Chemother* 2010; 65:1079-1085.
  8. McGovern BH, Abu Dayyeh BK, Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. *Hepatology*. 48(5):1700-12, 2008 Nov.
- **New Agents – Specific studies:**
    1. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *New Engl J Med*. 2009; 360:1827-1838.
    2. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *New Engl J Med* 2009; 360:1839-1850.
    3. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. *Lancet* 2010; 376:1467-75.
    4. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized multicenter phase 2 trial. *Lancet* 2010; 376:705-716.
    5. Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, et al. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG. *Gastroenterology* 2011; 140:755-760.e12.
    6. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection (SPRINT-2). *New Engl J Med* 2011; 364:1195-1206.
    7. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection (RESPOND-2). *New Engl J Med* 2011; 364:1207-1217.

### **New Prognostic Issues in Hepatitis C**

- **IL28B**
  1. Clark PJ, Thompson AJ, McHutchison JG. IL28B Genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies. *Am J Gastroenterol* 2011; 106:38-45.
  2. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology* 2010; 139:120-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/20399780>

3. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky J-M, et al. Hepatitis C pharmacogenetics: State of the Art in 2010. *Hepatology* 2011; 53:336-345.
  4. Chung RT. Reaping the early harvest of the genomics revolution. *Gastroenterology* 2010; 138:1653-1654.
  5. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009; 461:798-801. <http://www.ncbi.nlm.nih.gov/pubmed/19759533>
  6. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. *AIDS* 2010;24:F23-9. <http://www.ncbi.nlm.nih.gov/pubmed/20389235>
  7. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. *Hepatology* 2010; 52:1216-24. <http://www.ncbi.nlm.nih.gov/pubmed/20803561>
- **IL28B original studies**
    1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399-401.
    2. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and RBV therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105-1109.
    3. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML. IL28B is associated with response to chronic hepatitis C interferon-alpha and RBV therapy. *Nat Genet* 2009;41:1100-1104.
  - **Non-invasive Assessment of Liver Fibrosis**
    1. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. *Hepatology* 2011; 53:325-335.
    2. Mehta SH, Lau B, Afdhal NH, Thomas DL: Exceeding the limits of liver histology markers. *J Hepatol* 2009; 50:36-41.
    3. Moreno S, et al: Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. *J Viral Hepatitis* 2009; 16:249-258.
    4. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. *Hepatology* 2007; 46:32-36.

## **Public Health Issues in Hepatitis C**

- **Transmission and National Public Health Issues**

1. Institute of Medicine Report. Hepatitis and liver cancer: National strategy for prevention and control. Washington, DC; National Acad Press, January 2010.  
<http://www.iom.edu/Reports/2010/Hepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C.aspx>
2. Holmberg SD. Molecular epidemiology of health care-associated transmission of hepatitis B and C viruses. *Clin Liver Dis* 2010; 14:37-48.
3. Fischer GE, Schaefer MK, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. *Clin Infectious Diseases* 2010; 51:267-273.
4. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. *Annals Intern Med* 2009; 150:33-39.

- **Hepatitis C and Corrections**

1. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. *Hepatology* 2008; 48:1387-1395.
2. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. *Ann Intern Med*. 2003 Feb 4;138(3):187-90. PMID: 12558357
3. Federal Bureau of Prisons. Guidelines for the prevention and treatment of hepatitis C and cirrhosis. (Clinical Practice Guideline, June 2009) <http://www.bop.gov/news/medresources.jsp>.

- **The Cost of Hepatitis C Treatment**

1. Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. *J Hepatol* 2007; 47:608-617.
2. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. *J Viral Hepatitis* 2007; 14:107-115.
3. Shah BB, Wong JB. The economics of hepatitis C virus. *Clin Liver Dis* 2006; 10:717-734.

- **Acute Hepatitis C Infection**

1. Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, et al. Rare birds in North America: Acute hepatitis C cohorts. *Gastroenterology* 2009; 136:26-31.
2. Rockstroh JK, NEAT (The European AIDS Treatment network Acute Hepatitis C Infection consensus Panel). Acute hepatitis C in HIV-infected individuals – recommendations from the NEAT consensus conference. *AIDS* 2011; 25:in press.
3. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? *Hepatology* 2010; 52:1497-1505.
4. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. *Clinical Infectious Diseases* 2011; 52: 812-818.
5. van de Laar T, Pybus O, Bruisten S, Brown D, et al. Evidence of a large international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology* 2009; 136:1609-1617.
6. Taylor LE, Mayer KH. Acute hepatitis C virus infection in an HIV clinic and in community settings. *Gastroenterology* 2009; 136:2411-2412.

### **HIV Coinfection**

- **HIV Coinfection – General**

1. Treatment Action Group. Guide to hepatitis C for people living with HIV: Testing, coinfection, treatment, and support. (September 2008) [www.treatmentactiongroup.org](http://www.treatmentactiongroup.org).
2. Treatment Action Group. Guide to hepatitis B for people living with HIV. (June 2009) [www.treatmentactiongroup.org](http://www.treatmentactiongroup.org).
3. Sulkowski MS. Management of hepatic complication in HIV-infected persons. *J Infect Dis* 2008; 197:S279-S293.
4. Sherman KE, Soriano V, Chung RT. Human immunodeficiency virus and liver disease: conference proceedings. *Hepatology* 2010; 51:1046-54.
5. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. *Clinical Infectious Diseases* 2008; 47:94-101.
6. Bonacini M: Diagnosis and management of cirrhosis in coinfecting patients. *J AIDS* 2007; 45:S38-S46.

- **HIV Drug Toxicity**

1. Soriano V, Puoti M, et al: Antiretroviral drugs and liver injury. *AIDS* 2008; 22:1-13.
2. Merwat SN, Vierling JM: HIV Infection and the liver: The importance of HCV-HIV coinfection and drug-induced liver injury. *Clin Liver Disease* 2011; 15:131-152.
3. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ: Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. *J Acquir Immune Defic Syndr* 2008; 49:358-368
4. McGovern BH, Birch C, Zaman MT, et al.: Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon. *Clinical Infectious Diseases* 2007; 45:1386-92.

- **Nutrition, Metabolic Syndrome, Steatosis, and HCV**

1. Hendricks KM, Erzen HD, Wanke CA, Tang AM. Nutrition issues in the HIV-infected injection drug user: findings from the Nutrition for Healthy Living Cohort. *J Americal College of Nutrition* 2010; 29:136-143.
2. McGovern BH: Hepatic steatosis in HIV/HCV-coinfected patients: Time to reevaluate. *Gastroenterology* 2011; 140:772-775.
3. Kotler DP: Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions. *Liver International* 2009; 29:38-46.

### **Other Topics in Hepatitis C Management**

- **Psychiatry & Alcohol**

1. Angelino AF, Treisman GJ. Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. *International Review of Psychiatry* 2005; 17:471-476.
2. Litwin AH, Harris KA, Nahvi S, Zamor PJ, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. *J Subst Abuse Treat* 2009; 37:32-40.
3. Schäfer A, Wittchen H-U, Backmund M, Soyka M, Golz, J, et al. Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. *Addiction* 2009; 109:630-640.
4. Hauser P, Morasco BJ, Linke A, Bjornson D, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. *Psychosomatics* 2009; 50:500-505.

5. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? *Addiction* 2004; 99:1167-1175.
6. Edlin BR, Seal KH, Lorvick J, Kral AH, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? *New Engl J Med* 2001; 345:211-214.
7. Taylor LE, Gholam PM, Schwartzapfel B, Rich JD. Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report. *AIDS Read*. 2005 Nov; 5(11):629-31,634-6,638. PMID: 16323305
8. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. *Current Pharmaceutical Design* 2010; 16:2113-2117.
9. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: A frequently underestimated combination. *World J Gastroenterol* 2009; 15:3462-3471.
10. Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. *Seminars in Liver Disease* 2009; 29:188-199.